Biocon Pharma to Refund 340B Covered Entities for Overcharges, Amgen Introduces New NDCs

If you are already a paid subscriber, please follow the steps below.

• Please be sure you’ve completed your one-minute subscription completion form.
• I have read and accepted the terms of use and privacy policy.
• Log In!

If you are not yet a paid subscriber, please Subscribe now.

For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.